Lonza to expand bioconjugation facility

24 Jul 2019

Company also announces approval of third commercial ADC.

Lonza today announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third antibody-drug-conjugate (ADC) produced at the site. Building on 12 years of experience in the exacting bioconjugation space, Lonza’s expansion will meet the development and manufacturing needs of pharma and biotech companies developing a new generation of therapies.

Lonza to expand bioconjugation facility

Lonza’s Visp site completed a successful FDA inspection for commercial manufacture of a recently approved ADC, the third to be commercialized from the bioconjugation facility. The existing capacity at the Visp facility will cover the current needs for production of this fast-tracked therapy.

In addition, increasing demand from customers has prompted the Swiss contract development and manufacturing organization (CDMO) to commence an expansion that will span the next 2 years. The additional capacity, with contracts already in place, will provide current and future customers with launch and commercial manufacturing and will serve the rapidly expanding early clinical phase market for bioconjugates.

Bringing bioconjugates to market remains complex and Lonza is working at all stages of development and manufacturing - from expression systems with site-specific integration (SSI) vectors to a simplified supply chain with the option of all elements (antibody, linker and payload) under the same quality system. From 2020, all elements will be available at a single site through Ibex™Solutions and the newly expanded highly-potent API (HPAPI) facility. Furthermore, the recently announced addition of parenteral fill and finish gives customers the option of cGMP drug product as well as drug substance development and manufacturing.

Quote from Karen Fallen, Head of Mammalian and Microbial Development and Manufacturing, Lonza Pharma & Biotech: “With 11 INDs completed, and now three out of five commercially available ADCs supported by our bioconjugation facility, we see the need to expand in readiness for the new wave of therapies our customers are developing. Many bioconjugates are on expedited programs and the existing expertise at the facility, combined with proximity to clinical and commercial manufacturing of antibody, linkers and payload, will reduce risk and increase speed on the path to market.”

Quote from Thomas Rohrer, Head of Commercial Development Bioconjugates, Lonza Pharma & Biotech: “A high proportion of bioconjugates we deal with have accelerated approval and this latest approval was no exception. Meeting the tight deadlines of fast-tracked molecules requires seamless teamwork with the client and close collaboration to deliver the successful validation work required for launch of life-saving medications.”

Read More

Related categories

Related tags

Market News

Related news

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

15 Jan 2020

BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.

Read more 
Catalent launches direct-to-patient clinical supply services

Catalent launches direct-to-patient clinical supply services

14 Jan 2020

Multiple options provide increased flexibility for sponsors.

Read more 
Biogen to acquire novel clinical-stage asset from Pfizer

Biogen to acquire novel clinical-stage asset from Pfizer

14 Jan 2020

PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.

Read more 
French regulator agrees to partial resumption of Tellomak trial patient recruitment

French regulator agrees to partial resumption of Tellomak trial patient recruitment

14 Jan 2020

The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in ...

Read more 
Lupin could face FDA regulatory action over Tarapur API facility

Lupin could face FDA regulatory action over Tarapur API facility

13 Jan 2020

India’s Lupin Pharmaceuticals warned Monday it could face regulatory sanctions from the US Food and Drug Administration over its Tarapur active pharmaceutical ingredient (API) manufacturing facility.

Read more 
Partnership formed to develop and commercialise ready-to-use medicine

Partnership formed to develop and commercialise ready-to-use medicine

13 Jan 2020

The product being developed will use proprietary drug formulation technology platform Arestat to deliver new reformulations of existing, complex products.

Read more 
ReadCoor to commercially launch spatial sequencing platform

ReadCoor to commercially launch spatial sequencing platform

10 Jan 2020

Platform gives researchers access to previously undiscovered data to guide evaluation and validation of new drug targets, pathogen identification, disease diagnosis, and the advancement of regenerative medicine.

Read more 
CPhI and AAPS partner to expand expert scientific content at CPhI North America

CPhI and AAPS partner to expand expert scientific content at CPhI North America

10 Jan 2020

CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...

Read more 
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

9 Jan 2020

The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.

Read more 
New HQ for developer of world's first fully automated drug discovery platform

New HQ for developer of world's first fully automated drug discovery platform

8 Jan 2020

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Read more